Bli medlem
Bli medlem

Du är här

2016-05-18

Biotie Therapies Oyj: NORDEA BANK FINLAND PLC'S MARKET-MAKING FOR BIOTIE THERAPIES CORP.'S SHARE ENDS

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 May 2016,
at 6.20 p.m. (EET)

NORDEA BANK FINLAND PLC'S MARKET-MAKING FOR BIOTIE THERAPIES CORP.'S SHARE
ENDS

Biotie Therapies Corp. ("Biotie
") and Nordea Bank Finland Plc ("Nordea
") have jointly agreed to terminate the market-making agreement entered into
between Biotie and Nordea on 21 September 2009. The market-making ends on 20
June 2016.

Turku, 18 May 2016

Biotie Therapies Corp.
Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media

INFORMATION REGARDING BIOTIE

Biotie is a biopharmaceutical company focused on products for
neurodegenerative and psychiatric disorders. Biotie's development has
delivered Selincro (nalmefene) for alcohol dependence, which received
European marketing authorization in 2013 and is currently being marketed
across Europe by partner Lundbeck. The current development products include
tozadenant for Parkinson's disease, which is in Phase 3 development, and two
additional compounds which are in Phase 2 development for cognitive disorders
including Parkinson's disease dementia, and primary sclerosing cholangitis
(PSC), a rare fibrotic disease of the liver.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biotie Therapies Oyj via Globenewswire

HUG#2013694

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.